On Friday, the U.S. Food and Drug Administration gave the green light to Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) for MIMRYLO (rusfertide), a new treatment for polycythemia vera, a type of blood cancer. This is a first-in-class therapy, and it's a significant win for both Takeda and its development partner, Protagonist Therapeutics Inc. (NASDAQ: PTGX).
Takeda's New Blood Cancer Drug Wins FDA Approval, and It's a Big Deal for Protagonist Too
MarketDash
The FDA approved Takeda's MIMRYLO for polycythemia vera, a first-in-class treatment that controls hematocrit levels and reduces blood clot risks. The approval also triggers a $275 million payday for Protagonist Therapeutics.
Get Takeda Pharmaceutical Alerts
Weekly insights + SMS alerts
What Is Polycythemia Vera and Why Is It Dangerous?
Polycythemia vera is a condition where the body goes into overdrive producing red blood cells. That might sound like a good thing, but it's not. Too many red blood cells make the blood thicker, which dramatically increases the risk of blood clots. We're talking about serious, life-threatening events like strokes, pulmonary embolisms, and deep vein thrombosis.
To keep patients safe, doctors aim to keep hematocrit levels—the proportion of red blood cells in the blood—strictly below 45%. That's the magic number. Above that, the risk of clotting goes up significantly.
MIMRYLO works as a hepcidin mimetic. Hepcidin is a hormone that regulates iron in the body. By mimicking its action, MIMRYLO helps control iron distribution, which in turn stops the overproduction of red blood cells and keeps hematocrit in check. It's a clever mechanism that targets the root cause rather than just managing symptoms.
The VERIFY Study: The Evidence Behind the Approval
The FDA's decision was based on data from the global Phase 3 VERIFY study, which enrolled 293 patients with polycythemia vera. The trial met all its efficacy endpoints and showed a favorable safety profile. Patients who received MIMRYLO on top of their standard care had a higher response rate than those on placebo. They also had better hematocrit control, needed fewer routine phlebotomies (the old-school treatment of drawing blood to reduce red cell count), and reported less fatigue.
An open-label extension of the VERIFY trial is still ongoing, and Takeda plans to present more data at upcoming medical conferences. So there's more to come.
The Takeda-Protagonist Partnership
MIMRYLO's journey to approval is a story of collaboration. Protagonist Therapeutics discovered rusfertide (also known as PTG-300) and led its development through Phase 3. In 2024, Takeda entered into a worldwide license and collaboration agreement with Protagonist. Then, in April 2026, Protagonist exercised its opt-out rights for the U.S., meaning Takeda took over the NDA submission and commercialization.
That opt-out wasn't a bad deal for Protagonist. The FDA approval triggers $275 million in payments to Protagonist: a $200 million opt-out fee plus a $75 million approval milestone. And that's just the beginning. Protagonist is eligible for up to an additional $875 million in milestone payments, plus tiered royalties on worldwide net sales ranging from 14% to 29%. On a weighted-average basis, that works out to about 21% at $1.5 billion in annual sales. Not too shabby.
As for Takeda, the stock was down slightly on Monday, trading at $17.99, down 0.19% at the time of publication. But with a first-in-class drug now approved, the long-term outlook might be more interesting than the day-to-day tick.
This approval is a reminder that in the world of biotech, partnerships can be just as important as the science. And for patients with polycythemia vera, a new option that offers better control and fewer side effects is always welcome news.
More News
Stock Market Today: S&P 500, Dow Futures Slip as US-Iran Tensions Flare—WMT, RZLV, FNGR in Focus
Treasury Secretary Warns of 'Financial Violence' Against Iran, Banks Put on Notice
Trump's Iran Sanctions Take Aim at Banks, and China Might Be Next
Fed Rate Hike Bets Are Back: Is Warsh Turning Into an Inflation Hawk?
Iran's President Admits Sanctions Are Biting as Oil Trade Slumps and Gas Lines Grow
Oil Spikes on Iran Strikes, California Utilities Get Torched: Market Recap
GM Workers Greenlight Deal to Build Next-Gen GMC Sierra in Ontario as Trump Tariff Threats Loom
Ford to Trump: Stop Bullying Canada, Tariffs Are a Tax on Americans
Get Takeda Pharmaceutical Alerts
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
Featured Articles
View all newsStock Market Today: S&P 500, Dow Futures Slip as US-Iran Tensions Flare—WMT, RZLV, FNGR in Focus
By MarketDash
August 31, 2026
Treasury Secretary Warns of 'Financial Violence' Against Iran, Banks Put on Notice
By MarketDash
August 31, 2026
Trump's Iran Sanctions Take Aim at Banks, and China Might Be Next
By MarketDash
August 31, 2026
Fed Rate Hike Bets Are Back: Is Warsh Turning Into an Inflation Hawk?
By MarketDash
August 31, 2026
Iran's President Admits Sanctions Are Biting as Oil Trade Slumps and Gas Lines Grow
By MarketDash
August 31, 2026
Oil Spikes on Iran Strikes, California Utilities Get Torched: Market Recap
By MarketDash
August 31, 2026
GM Workers Greenlight Deal to Build Next-Gen GMC Sierra in Ontario as Trump Tariff Threats Loom
By MarketDash
August 31, 2026
Ford to Trump: Stop Bullying Canada, Tariffs Are a Tax on Americans
By MarketDash
August 31, 2026